203 related articles for article (PubMed ID: 33441719)
1. Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients.
Fudaba H; Momii Y; Hirakawa T; Onishi K; Asou D; Matsushita W; Kawasaki Y; Sugita K; Fujiki M
Sci Rep; 2021 Jan; 11(1):1206. PubMed ID: 33441719
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
3. Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma.
Chen Q; Chen B; Wang C; Hu L; Wu Q; Zhu Y; Zhang Q
Front Immunol; 2023; 14():1159085. PubMed ID: 37234161
[TBL] [Abstract][Full Text] [Related]
4. Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma.
Sun X; Wang C; Chen C; Huang J; Wu X; Wang Y; He X; Cao J; Jiang W; Sun P; Li Z
Hematol Oncol; 2021 Dec; 39(5):625-638. PubMed ID: 34543472
[TBL] [Abstract][Full Text] [Related]
5. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.
Zhou S; Wang Y; Zhang R; Zeng W; Liu S; Liu S; Liu M; Yang H; Xi M
JAMA Netw Open; 2023 Jan; 6(1):e2250965. PubMed ID: 36648946
[TBL] [Abstract][Full Text] [Related]
6. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).
Berghoff AS; Ricken G; Widhalm G; Rajky O; Hainfellner JA; Birner P; Raderer M; Preusser M
Clin Neuropathol; 2014; 33(1):42-9. PubMed ID: 24359606
[TBL] [Abstract][Full Text] [Related]
7. Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system.
Tsuyuki Y; Ishikawa E; Kohno K; Shimada K; Ohka F; Suzuki Y; Mabuchi S; Satou A; Takahara T; Kato S; Miyagi S; Ozawa H; Kawano T; Takagi Y; Hiraga J; Wakabayashi T; Nakamura S
Neuropathology; 2021 Apr; 41(2):99-108. PubMed ID: 33269495
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma.
Zhao J; Yang H; Hu H; Liu C; Wei M; Zhao Y; Chen Y; Cui Y; Chen P; Xiong K; Lu Y; Yang H; Yang L
Sci Rep; 2022 Jun; 12(1):10401. PubMed ID: 35729260
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
10. Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma.
Huang Z; Guo Y; Li B; Shen M; Yi Y; Li L; Zhao X; Yang L
Cancer Gene Ther; 2024 Mar; 31(3):427-438. PubMed ID: 38072971
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
[TBL] [Abstract][Full Text] [Related]
12. Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy.
Sun J; Lu Q; Sanmamed MF; Wang J
Clin Cancer Res; 2021 Feb; 27(3):680-688. PubMed ID: 32958700
[TBL] [Abstract][Full Text] [Related]
13. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
14. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma.
Chen X; Mo S; Zhang Y; Ma H; Lu Z; Yu S; Chen J
J Pathol Clin Res; 2022 May; 8(3):268-278. PubMed ID: 35083884
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
[TBL] [Abstract][Full Text] [Related]
16. Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.
Hayano A; Komohara Y; Takashima Y; Takeya H; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Yamanaka R
Anticancer Res; 2017 Oct; 37(10):5655-5666. PubMed ID: 28982883
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
18. The role of comorbidity indices and histochemical markers in surgically resected and non-resected primary central nervous system lymphoma.
Wong CE; Liao WA; Chang Y; Lee PH; Huang CC; Chang KC; Lee JS
Clin Exp Med; 2023 Nov; 23(7):3799-3807. PubMed ID: 37491648
[TBL] [Abstract][Full Text] [Related]
19. The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma.
Miyasato Y; Takashima Y; Takeya H; Yano H; Hayano A; Nakagawa T; Makino K; Takeya M; Yamanaka R; Komohara Y
J Clin Exp Hematop; 2018; 58(2):95-101. PubMed ID: 29998979
[TBL] [Abstract][Full Text] [Related]
20. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
